"Which weight-loss injection is best?" is one of the most common questions UK patients bring to a consultation. It is also one of the hardest to answer in a sentence. The honest answer is that the medicines work in similar but not identical ways, the trial-level numbers differ, and the right choice for you is not the one with the biggest headline figure — it is the one that fits your medical picture, your tolerability and your goals. This guide walks through what we know, what we don't, and how a UK clinician actually decides with you.

What "best" really means in clinical practice

In medicine, "best" is rarely a single product on a shelf. The same medicine can be transformative for one patient and a poor fit for another, even when both share a similar starting weight. A more useful question is: which medicine is most likely to be effective and tolerable for this patient, with these comorbidities, on this budget, given this goal? That is a clinical conversation, not a comparison table.

Trial averages are useful guides — they tell us what tends to happen for a group of patients in tightly controlled conditions. They are less useful as personal predictions. Some patients on the medicine with the smaller average effect end up losing more weight than the group average for the medicine with the larger average effect. Variation between individuals is the rule, not the exception.

How Mounjaro and Wegovy compare on the data

In the UK, the two main GLP-1-based weight-management injections are Mounjaro (tirzepatide) and Wegovy (semaglutide). Both are once-weekly subcutaneous injections delivered by pre-filled pen. Both work by mimicking gut hormones that influence appetite, satiety and post-meal blood-glucose response. The key difference is that tirzepatide is a dual GIP/GLP-1 receptor agonist, while semaglutide acts on GLP-1 receptors only — a mechanistic difference that may help explain why the average weight-loss outcomes differ.

The most-cited trial-level signals come from the SURMOUNT-1 study of tirzepatide and the STEP-1 study of semaglutide. In SURMOUNT-1, adults living with obesity (without type 2 diabetes) on the highest tirzepatide dose achieved an average weight reduction of about 22% over 72 weeks. In STEP-1, adults on 2.4 mg semaglutide achieved an average reduction of about 15% over 68 weeks. These trials were not head-to-head — the populations, durations and protocols differed — so the comparison is indicative rather than definitive. Even so, the direction of effect is consistent across multiple analyses: tirzepatide tends to produce larger mean weight loss than semaglutide at the doses studied.

Useful caveats to keep in mind:

  • These are group averages, not personal predictions. Individual response varies widely.
  • Both trials included intensive lifestyle support alongside the medicine.
  • Real-world results often differ from trial conditions, partly because tolerability and adherence in everyday life are not the same as in a trial.
  • The full benefit of either medicine takes months to emerge, and weight loss continues over a year or more for many patients who stay on treatment.

Side-effect profile differences

Side-effect profiles for tirzepatide and semaglutide overlap heavily but are not identical. The dominant story for both is gastrointestinal: nausea, reduced appetite, constipation and, less commonly, loose stools. These are most pronounced in the first one to two weeks at each new dose and usually settle as the body adapts. This is why both medicines are titrated slowly, with at least four weeks at each step before considering an increase. We cover what that pattern looks like in more detail in our guide on when to increase your Mounjaro dose for weight loss.

What the trials and real-world reports suggest about differences:

  • Some patients find tirzepatide marginally less nauseating at equivalent stages of titration; others find the opposite. There is no reliable way to predict which without trying.
  • Both medicines can cause early-treatment fatigue, reflux and a general "off" feeling for a few days after a dose change.
  • Rare but serious risks — pancreatitis, gallbladder events, severe dehydration, allergic reactions — are recognised for both and are listed in the BNF and the UK Summary of Product Characteristics.
  • Patients with a history of frequent gallstones, severe gastroparesis or pancreatitis need careful clinician review before either medicine is offered.

If side effects make life difficult, the answer is rarely "stop and switch immediately". It is usually to hold at the current dose for longer, manage symptoms practically (smaller meals, more water, fibre, easing off rich foods around injection day), and review with your clinician. We dig into that further in can I stay on a low dose of Wegovy?, which applies to either medicine in principle.

UK licensing and access differences

Both medicines are licensed in the UK by the MHRA for use in adults living with obesity, or with overweight plus weight-related comorbidities, alongside diet and physical activity. NHS access to either medicine for weight management is limited and is usually delivered through specialist weight-management services, with specific BMI thresholds and comorbidity criteria set by NICE. Many patients who would benefit do not meet the NHS eligibility threshold, or face long waits within tier-3/tier-4 weight-management pathways.

As a result, most UK patients access these treatments through regulated private prescription routes — a GPhC-registered pharmacy clinic with a UK prescriber, an initial consultation, a structured titration plan and ongoing monitoring. Choosing a clinic that requires a real clinician consultation, asks about medical history and contraindications, and reviews progress over time is part of the safety picture, not an optional extra. Tirzepatide is licensed for both type 2 diabetes and weight management; semaglutide (Wegovy specifically) is licensed for weight management — semaglutide under the brand Ozempic is licensed for type 2 diabetes only and is not the same product as Wegovy.

How a clinician chooses between them with you

In a consultation, several factors shape the choice — and the right answer is sometimes "either is reasonable; let's pick based on tolerability and access":

  • Starting BMI and goals. For patients with very high starting BMI or ambitious agreed goals, the trial-level signal favouring tirzepatide may matter more. For someone with a more modest goal, both medicines may work well enough that other factors decide.
  • Comorbidities. Type 2 diabetes, cardiovascular risk, kidney function and gastrointestinal history all influence the choice. Tirzepatide's dual GIP/GLP-1 action makes it particularly useful where diabetes is also being treated.
  • Prior experience with GLP-1 medicines. If you have tried semaglutide and tolerated it poorly, a switch to tirzepatide is worth discussing — and vice versa. Tolerability of one does not predict the other.
  • Side-effect tolerance and lifestyle. If your work or caring responsibilities make a week of strong nausea after a dose increase impossible, slower titration on either medicine is the safer choice.
  • Access and cost. Price, pen availability, supply stability and continuity of clinic care are practical factors that affect whether you can stay on a medicine long enough to see benefit.
  • Pregnancy plans. Neither medicine is appropriate during pregnancy. If pregnancy is planned within the next year, the conversation changes.

"Best" then becomes a sentence, not a label: the best injection for you is the one your clinician and you choose together, on a plan you can stay on, with reviews that catch problems early. If you want to read more about how response is usually paced, see how long does it take for Mounjaro to work? — the dynamics are similar for semaglutide.

Whichever medicine you start with, treat the early weeks as learning weeks, not result weeks. Your clinician will advise based on your individual circumstances, set realistic expectations, and adjust if something is not working. The goal is sustainable progress on a treatment you can live with — not the medicine with the biggest headline number.